City

Kanto Region (1)

Shirakawa (1)

Condition

Agitation Associated With Dementia of the Alzheimer's Type (2)

Overall Status

Completed (1)

Terminated (1)

Sign in for free

Phase

phase 3 (2)

Sponsor

Otsuka Pharmaceutical Co., Ltd. (2)

Collaborator

Intervention

2 mg/day (1)

3 mg/day (1)

6 mg/day (1)

brexpiprazole (1)

placebo (0 mg/day) (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (2)

Study Type

Interventional (2)

agitation associated with dementia of the alzheimer's type

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Agitation Associated With Dementia of the Alzheimer's Type Trial in Shirakawa (Brexpiprazole)

Completed

Agitation Associated With Dementia of the Alzheimer's Type

Brexpiprazole

Shirakawa, Japan

Jisenkai Nanko Psychiatric Institute

Jan 12, 2022

Agitation Associated With Dementia of the Alzheimer's Type Trial in Kanto Region (2 mg/day, 3 mg/day, 6 mg/day)

Terminated

Agitation Associated With Dementia of the Alzheimer's Type

2 mg/day
+3 more

Kanto Region, Japan

(unnamed)

Oct 13, 2017